---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125376"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:58:48.043460+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics Q3 2024: cash $84.4M; BDC-3042 advances to 10 mg/kg cohort

## Summary
- Cash $84.4M as of Sept 30, 2024; expected to fund operations through mid-2026.
- Q3 operating loss $16.4M vs $18.2M in Q3 2023; R&D expenses $13.8M, G&A $3.8M.
- BDC-3042 Phase 1 advanced to 10 mg/kg cohort; data update expected H1 2025.
- BDC-4182 on track for clinical trial start in Q2 2025; preclinical data at SITC.
- Collaboration revenue $1.1M, down from $2.5M in prior-year quarter.

## SEC filing metadata
- accession: 0000950170-24-125376
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017024125376/0000950170-24-125376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017024125376/bolt-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125376
- JSON: https://secwatch.observer/filing/0000950170-24-125376.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125376.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.